Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoSFERIC cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Sferogen
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The nanoSFERIC cancer vaccine is an early-stage, protein nanoparticle-based immunotherapy currently in preclinical development by Sferogen for the treatment of various oncology indications. Utilizing Sferogen's proprietary nanoSFERIC platform, the vaccine is engineered to present tumor-associated antigens (TAAs) in a highly organized, multivalent format. This structural arrangement is designed to mimic the repetitive patterns of pathogens, thereby enhancing recognition and uptake by antigen-presenting cells (APCs). The primary goal of the vaccine is to stimulate a robust and specific anti-tumor immune response, potentially involving the activation of cytotoxic T lymphocytes and the production of antibodies to target and eliminate malignant cells expressing the specific cancer antigens.
- Other names
- Sferogen cancer vaccinenanoSFERIC protein nanoparticle cancer vaccineSferogen cancer antigen vaccine
Beyond the preview
Go deeper on nanoSFERIC cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoSFERIC cancer vaccine.